Announcement on Provision for Asset Impairment in 2024
Filed with SSE · · 3 pages · Chinese
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on Change of Sponsor Institution and Sponsor Representative
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment
- Announcement on Obtaining Government Subsidy
Later from Chengdu Olymvax Biopharmaceuticals
- Announcement on Convening 2024 Annual Performance and Cash Dividend Briefing
- Announcement on Resolutions of 2024 Annual General Meeting
- Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and the Q1 2025 Performance Briefing
- Indicative Announcement on Postponing Term Change of Board of Directors and Board of Supervisors and Expiration of Term of Independent Director
- Announcement on Release of Pledge of Some Shares Held by Shareholders with Over 5% Shares
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals